TRHC to Present at HIMSS19 - Tabula Rasa HealthCare

TRHC to Present at HIMSS19

Press Releases | Feb 08, 2019

MOORESTOWN, N.J., February 8, 2019 – Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced that Chairman and CEO Calvin H. Knowlton, Ph.D., will present at the Healthcare Information and Management Systems Society (HIMSS) 2019 annual meeting – the leading health information and technology conference – in Orlando, Florida.

Dr. Knowlton’s presentation will focus on the expanded use of TRHC’s proprietary Medication Risk Mitigation technology, MedWise™, through its new state-of-the-art SMART on FHIR integration. The integration will allow more pharmacists and care providers to access TRHC’s technology directly from their electronic health record (EHR) system, at the point of care. This includes access to MedWise’s simultaneous, accumulative multi-drug interaction assessment that identifies medication-related risk and presents actionable opportunities for clinicians to prevent adverse drug events (ADEs) – the fourth leading cause of death in the U.S. MedWise also produces a Medication Risk Score for each patient that has been shown to correlate directly with medical expenditures: the lower the risk score, the lower the costs.

The presentation will take place on Thursday, February 14, 2019 at 10:45 am ET in the Innovation Live Pavilion (Theater 1). TRHC will also showcase more of its medication risk management solutions, including the newly-launched version of its medication decision support software, MedWise 2.0, at kiosk IK39.

MedWise is based on TRHC’s proprietary technology for predicting safety risk and ADEs associated with polypharmacy. MedWise translates the pharmacokinetics and pharmacodynamics associated with a patient’s medication regimen to formulate meaningful and actionable views of each risks. The technology empowers prescribers to take a more personalized approach to medication management, including medication selection, dosage levels, time-of-day administration and reduction of the total number of medications by eliminating unnecessary prescriptions.

Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2018, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Share this:
Fill 1 Copy 2closeFill 5 Copy 4green-arrowhamburgerFill 7 Copy 4Fill 1 Copy 4pauseplaysearch-iconFill 3 Copy 4